Genital Infection / UTI
How frequently do genital infections (e.g. candidiasis) occur with Empagliflozin in patients with HF?
Rates of genital infections in the HF Trials
EMPEROR-Reduced:1,2
1.7%
No T2D 1.4%
0.6%
No T2D 0.9%
EMPEROR-Preserved:3,4
2.2%
No T2D 2.0%
0.7%
No T2D 0.5%
Empagliflozin
Placebo
- In both trials, a higher proportion of patients in the empagliflozin group had genital infections than patients in the placebo group1,3
- However, the number of patients with complicated genital infections was low and rates were the same for both treatment groups in both trials (0.3% of patients)1,3
Note:
- HF, heart failure; T2D, type 2 diabetes; UTI, urinary tract infection.
- 1. Packer M et al. N Engl J Med. 2020;383:1413; 2. Anker SD et al. Circulation. 2021;143:337; 3. Anker S et al. N Engl J Med. 2021;385:1451; 4. Filippatos G et al. Presented at EASD 2021, 30 September 2021.